Humana Stock Hits 52-Week High After Medicare Ratings Boost

10/9/2026
Impact: 80
Healthcare

Humana Inc. announced that 95% of its Medicare Advantage members are enrolled in plans rated at least four stars by the Centers for Medicare and Medicaid Services for 2027, contributing to a 16.09% increase in its stock price to $449.41, marking a new 52-week high. The company secured six contracts with a 4.5-star distinction and 12 contracts with a 4.0-star rating, an increase of 11 contracts compared to the previous year. Humana reaffirmed its fiscal 2026 adjusted earnings guidance of at least $9 per share, aligning closely with the consensus estimate of $9.15.

AI summary, not financial advice

Share: